Hosted by IDTechEx
Truly Global Daily News Interpreted by Experts
HomeEventsReportsTVCareersAbout UsSign-up or LoginIDTechExTwitterLinkedInGoogle+YoutubeRSSForward To Friend
Posted on September 13, 2017

Investment sought for 3D printed hearts

Printed and Flexible Sensors 2017-2027: Technologi
BIOLIFE4D announced it filed a $50 million initial public offering with the Securities and Exchange Commission (SEC) under Regulation A+ rules, allowing everyday investors to help the company bring its groundbreaking cardiac tissue regeneration and organ replacement process to market.
 
Chicago-based BIOLIFE4D is a pioneering biotech company focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant. The company plans to use proceeds from the offering to bolster working capital and fund key corporate initiatives including hiring additional employees to supplement its world-class science advisory team, procuring laboratory space, and developing and licensing related technology.
 
BIOLIFE4D's approach will converge recent breakthroughs in regenerative medicine, stem cell biology, 3D printing techniques and computing technology in their effort to make organ replacement commercially viable and commonplace globally.
 
The company's primary focus is to perfect the technology to make viable organ replacement a safe, accessible and affordable reality. With BIOLIFE4D, a patient-specific, fully functioning heart will be created through 3D bioprinting and the patient's own cells, eliminating the challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods.
 
IDTechEx TV add
"Heart disease is the leading cause of death worldwide - killing one in four men and one in three women while outpacing all forms of cancer combined," said BIOLIFE4D CEO Steven Morris. "BIOLIFE4D is committed to transforming the treatment of heart disease, capitalizing on recent medical breakthroughs and optimizing a process that will ultimately give patients the gift of time."
 
Under the 2012 Jumpstart Our Business Startups Act, or JOBS Act, companies can raise up to $50 million in equity from investors — including non-accredited investors — according to "Reg A+" rules. Previously, companies were limited to raising $5 million under the past Regulation A rules.
 
Equity and other forms of crowdfunding are an increasingly popular way to raise capital while allowing large numbers of people to invest. Early crowdfunding adopters raised a reported $880 million in 2010, and today the crowdfunding industry exceeds $34 billion globally.
 
"BIOLIFE4D is bringing revolutionary life-saving care to the masses, and we want the masses to have a chance to be a part of this revolution," said Morris. "Equity crowdfunding can help us accomplish this important objective, and we're extremely excited for interested investors to join us."
 
Webinars Generic Banner
BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant - lifesaving technology that gives patients the gift of time. With BIOLIFE4D, a patient-specific, fully functioning heart will be created through 3D bioprinting using the patient's own cells - eliminating the well-known challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods.
 
Source and top image: BIOLIFE4D
Learn more at the next leading event on the topic: Business and Technology Insight Forum. Japan 2017 External Link on 27 - 29 Sep 2017 in Tokyo, Japan hosted by IDTechEx.